Rationale and Patient Selection for “Hybrid” Drug and Device Therapy in Atrial and Ventricular Arrhythmias

Three quite different forms of direct antiarrhythmic therapy are available for the treatment of cardiac arrhythmias: antiarrhythmic drugs, cardiac ablation and implantable devices (pacemakers and defibrillators). None of these therapies is fully effective and consequently they are increasingly combined. This combination therapy is often described as “hybrid” a term that implies fundamental different qualities of treatment which together provide some form of synergism. The mechanisms for the initiation and perpetuation of most cardiac arrhythmias are complex and multiple. It is therefore not surprising that single therapies are not completely effective. Theoretically the use of multiple different therapies allows more specific mechanisms of arrhythmia to be directly addressed. However, this is largely a theoretical concept that has only been strictly evaluated in a small number of studies. Studies of multiple therapies are difficult to perform unless the combination therapy is regarded as a strategy which can be compared to baseline, conventional treatment or one or more single constituent therapies from the combination. Despite the lack of formal studies there is a very substantial clinical experience which testifies to the value of hybrid therapy for the management of both atrial fibrillation and ventricular tachycardia/fibrillation.